Farooqi Lab
@farooqi-lab.bsky.social
Professor Sadaf Farooqi’s lab at the University of Cambridge. We study the fundamental mechanisms controlling human energy homeostasis to identify treatments for obesity.
With thanks to our colleagues, collaborators, funders and most importantly, all the participants in our studies @cambridgebrc.bsky.social @wellcometrust.bsky.social @ims-mrl.bsky.social, Rare Disease UK (
@rarediseaseuk on X) and the Cambridge Metabolic Network (@CamMetaboNet on X)
(6/6)
@rarediseaseuk on X) and the Cambridge Metabolic Network (@CamMetaboNet on X)
(6/6)
October 16, 2025 at 11:18 AM
With thanks to our colleagues, collaborators, funders and most importantly, all the participants in our studies @cambridgebrc.bsky.social @wellcometrust.bsky.social @ims-mrl.bsky.social, Rare Disease UK (
@rarediseaseuk on X) and the Cambridge Metabolic Network (@CamMetaboNet on X)
(6/6)
@rarediseaseuk on X) and the Cambridge Metabolic Network (@CamMetaboNet on X)
(6/6)
People with MC4R deficiency will likely benefit from Tirzepatide and should have access to it.
(5/6)
(5/6)
October 16, 2025 at 11:18 AM
People with MC4R deficiency will likely benefit from Tirzepatide and should have access to it.
(5/6)
(5/6)
In a second paper in Nature Medicine, we showed that people with MC4R deficiency in the SUSTAIN-1 trial, lost weight with Tirzepatide. The amount of weight lost was comparable to people with common obesity.
DOI: doi.org/10.1038/s415...
(4/6)
DOI: doi.org/10.1038/s415...
(4/6)
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency - Nature Medicine
Analyzing data from the SURMOUNT-1 trial, the authors show that the weight loss effects of tirzepatide treatment are similar in carriers and noncarriers of MC4R pathogenic mutations.
doi.org
October 16, 2025 at 11:18 AM
In a second paper in Nature Medicine, we showed that people with MC4R deficiency in the SUSTAIN-1 trial, lost weight with Tirzepatide. The amount of weight lost was comparable to people with common obesity.
DOI: doi.org/10.1038/s415...
(4/6)
DOI: doi.org/10.1038/s415...
(4/6)
These studies demonstrate that brain MC4Rs regulate human lipid metabolism. Further studies could provide new approaches to reducing cardiovascular disease risk.
(3/6)
(3/6)
October 16, 2025 at 11:18 AM
These studies demonstrate that brain MC4Rs regulate human lipid metabolism. Further studies could provide new approaches to reducing cardiovascular disease risk.
(3/6)
(3/6)
Despite severe obesity, MC4R deficient people had lower LDL-cholesterol, triglycerides and cardiovascular risk compared to people in UK Biobank of the same age and BMI.
(2/6)
(2/6)
October 16, 2025 at 11:18 AM
Despite severe obesity, MC4R deficient people had lower LDL-cholesterol, triglycerides and cardiovascular risk compared to people in UK Biobank of the same age and BMI.
(2/6)
(2/6)
In a paper just published in Nature Medicine, we characterised the largest cohort of people with loss-of-function mutations in the Melanocortin 4 receptor (MC4R) gene.
DOI: doi.org/10.1038/s415...
(1/6)
DOI: doi.org/10.1038/s415...
(1/6)
Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk - Nature Medicine
The authors explore the impact of MC4R deficiency on lipid metabolism in humans, based on two large cohorts. Findings indicate that individuals with obesity due to MC4R deficiency have lower cholester...
doi.org
October 16, 2025 at 11:18 AM
In a paper just published in Nature Medicine, we characterised the largest cohort of people with loss-of-function mutations in the Melanocortin 4 receptor (MC4R) gene.
DOI: doi.org/10.1038/s415...
(1/6)
DOI: doi.org/10.1038/s415...
(1/6)
Reposted by Farooqi Lab
👏Many congratulations👏 to Professor Sadaf Farooqi
@farooqi-lab.bsky.social for being honoured with the prestigious Gerald D Aurbach Award by the Endocrine Society
for Outstanding Translational Research
More👉 bit.ly/46gFx1d
@ims-mrl.bsky.social @cuh.nhs.uk @cam.ac.uk @endocrinesociety.bsky.social
@farooqi-lab.bsky.social for being honoured with the prestigious Gerald D Aurbach Award by the Endocrine Society
for Outstanding Translational Research
More👉 bit.ly/46gFx1d
@ims-mrl.bsky.social @cuh.nhs.uk @cam.ac.uk @endocrinesociety.bsky.social
Cambridge Professor honoured with prestigious Endocrine Society award, marking a second consecutive win for Metabolic Science at the Biomedical Research Centre - NIHR Cambridge Biomedical Research Cen...
Professor Farooqi has been awarded the esteemed Gerald D. Aurbach Award for Outstanding Translational Research. This is the second year running that a Cambridge BRC researcher in the field of metaboli...
bit.ly
September 10, 2025 at 2:54 PM
👏Many congratulations👏 to Professor Sadaf Farooqi
@farooqi-lab.bsky.social for being honoured with the prestigious Gerald D Aurbach Award by the Endocrine Society
for Outstanding Translational Research
More👉 bit.ly/46gFx1d
@ims-mrl.bsky.social @cuh.nhs.uk @cam.ac.uk @endocrinesociety.bsky.social
@farooqi-lab.bsky.social for being honoured with the prestigious Gerald D Aurbach Award by the Endocrine Society
for Outstanding Translational Research
More👉 bit.ly/46gFx1d
@ims-mrl.bsky.social @cuh.nhs.uk @cam.ac.uk @endocrinesociety.bsky.social
Thank you to the @endocrinesociety.bsky.social for this prestigious honour!
Congratulations to the 2026 Laureate Award Recipients | We celebrate the highest achievements in endocrinology across research, clinical care, leadership, mentorship, innovation, and service. View the winners: bit.ly/4876pTF #ENDO2026 #endocrinology #EndoSky
September 10, 2025 at 1:38 PM
Thank you to the @endocrinesociety.bsky.social for this prestigious honour!
Reposted by Farooqi Lab
🙌Many congratulations to all winners, but in particular our very own Professor Sadaf Farooqi as recipient of the Gerald D. Aurbach Award for Outstanding Translational Research.
ℹ️https://www.mrl.ims.cam.ac.uk/news/professor-sadaf-farooqi-honoured-endocrine-society-2026-laureate-award
ℹ️https://www.mrl.ims.cam.ac.uk/news/professor-sadaf-farooqi-honoured-endocrine-society-2026-laureate-award
September 10, 2025 at 1:22 PM
🙌Many congratulations to all winners, but in particular our very own Professor Sadaf Farooqi as recipient of the Gerald D. Aurbach Award for Outstanding Translational Research.
ℹ️https://www.mrl.ims.cam.ac.uk/news/professor-sadaf-farooqi-honoured-endocrine-society-2026-laureate-award
ℹ️https://www.mrl.ims.cam.ac.uk/news/professor-sadaf-farooqi-honoured-endocrine-society-2026-laureate-award
Professor Farooqi to receive 2026 Laureate Award from @endocrinesociety.bsky.social!
Details on Endocrine Society website and here:
www.goos.org.uk/resource-cen...
Details on Endocrine Society website and here:
www.goos.org.uk/resource-cen...
Professor Sadaf Farooqi receives Gerald D. Aurbach Award for Outstanding Translational Research 2026 Laureate Award from the Endocrine Society - Genetics of Obesity Study
www.goos.org.uk
September 10, 2025 at 1:37 PM
Professor Farooqi to receive 2026 Laureate Award from @endocrinesociety.bsky.social!
Details on Endocrine Society website and here:
www.goos.org.uk/resource-cen...
Details on Endocrine Society website and here:
www.goos.org.uk/resource-cen...
#4
With thanks to our collaborators and funders @cambridgebrc.bsky.social @wellcometrust.bsky.social @tesscacciottolo.bsky.social
With thanks to our collaborators and funders @cambridgebrc.bsky.social @wellcometrust.bsky.social @tesscacciottolo.bsky.social
September 3, 2025 at 10:00 AM
#4
With thanks to our collaborators and funders @cambridgebrc.bsky.social @wellcometrust.bsky.social @tesscacciottolo.bsky.social
With thanks to our collaborators and funders @cambridgebrc.bsky.social @wellcometrust.bsky.social @tesscacciottolo.bsky.social
#3
And the benefits of GCGR agonists which reduce liver fat in people with obesity and MASLD.
@rarediseaseuk (on X) @CamMetaboNet (on X) @ims-mrl.bsky.social
And the benefits of GCGR agonists which reduce liver fat in people with obesity and MASLD.
@rarediseaseuk (on X) @CamMetaboNet (on X) @ims-mrl.bsky.social
September 3, 2025 at 10:00 AM
#3
And the benefits of GCGR agonists which reduce liver fat in people with obesity and MASLD.
@rarediseaseuk (on X) @CamMetaboNet (on X) @ims-mrl.bsky.social
And the benefits of GCGR agonists which reduce liver fat in people with obesity and MASLD.
@rarediseaseuk (on X) @CamMetaboNet (on X) @ims-mrl.bsky.social
#2
Results are relevant for understanding the risks associated with GCGR antagonists which have been trialled in people with type 2 diabetes.
Results are relevant for understanding the risks associated with GCGR antagonists which have been trialled in people with type 2 diabetes.
September 3, 2025 at 10:00 AM
#2
Results are relevant for understanding the risks associated with GCGR antagonists which have been trialled in people with type 2 diabetes.
Results are relevant for understanding the risks associated with GCGR antagonists which have been trialled in people with type 2 diabetes.
#1
In a paper just published online in Diabetes, we showed that homozygous loss-of-function mutations in the Glucagon receptor (GCGR) cause early-onset hepatic steatosis in people.
DOI: doi.org/10.2337/db25...
In a paper just published online in Diabetes, we showed that homozygous loss-of-function mutations in the Glucagon receptor (GCGR) cause early-onset hepatic steatosis in people.
DOI: doi.org/10.2337/db25...
September 3, 2025 at 10:00 AM
#1
In a paper just published online in Diabetes, we showed that homozygous loss-of-function mutations in the Glucagon receptor (GCGR) cause early-onset hepatic steatosis in people.
DOI: doi.org/10.2337/db25...
In a paper just published online in Diabetes, we showed that homozygous loss-of-function mutations in the Glucagon receptor (GCGR) cause early-onset hepatic steatosis in people.
DOI: doi.org/10.2337/db25...